ALX Oncology Holdings
General Information | |
Business: |
We are a clinical stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Cancer cells leverage CD47, a cell surface protein, as a “don’t eat me” signal, to evade detection by the immune system. Our company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 24 |
Founded: | 2015 |
Contact Information | |
Address | 866 Malcolm Road, Suite 100 Burlingame, CA 94010, US |
Phone Number | 650-466-7125 |
Web Address | http://alxoncology.com |
View Prospectus: | ALX Oncology Holdings |
Financial Information | |
Market Cap | $555.4mil |
Revenues | $4.4 mil (last 12 months) |
Net Income | $-25.6 mil (last 12 months) |
IPO Profile | |
Symbol | ALXO |
Exchange | NASDAQ |
Shares (millions): | 8.5 |
Price range | $19.00 - $19.00 |
Est. $ Volume | $161.5 mil |
Manager / Joint Managers | Jefferies/ Credit Suisse/ Piper Sandler/ Cantor |
CO-Managers | LifeSci Capital |
Expected To Trade: | 7/17/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |